Company Overview of Bicycle Therapeutics Limited
Bicycle Therapeutics Limited, a biotherapeutics company, focuses on developing highly constrained bicyclic peptides (bicycles) as novel class of therapeutics. The company is involved in developing a pipeline of bicycle molecules by using its proprietary bicyclic peptide technology that provide antibody-like affinity and selectivity in a much smaller chemically synthesized molecule. It applies its technology to various drug discovery projects, including oncology, ophthalmology, and other therapeutic areas through collaborative discovery partnerships with pharmaceutical companies. Bicycle Therapeutics Limited was founded in 2009 and is based in Cambridge, United Kingdom.
Babraham Research Campus
Cambridge, CB22 3AT
Founded in 2009
Key Executives for Bicycle Therapeutics Limited
President and Chief Business Officer
Co-Founder, Director and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2015.
Bicycle Therapeutics Limited Key Developments
Bicycle Therapeutics Limited Appoints Arvind Hundal as a President & Chief Business Officer
May 11 15
Bicycle Therapeutics Limited appointed Arvind Hundal as President & Chief Business Officer. Dr. Hundal has more than 20 years experience in the life sciences sector, the majority of which have been in business development and strategy roles. She was most recently Chief Business Officer and Senior Management Team Member of Zealand Pharma A/S and was a part of the team that lead the successful initial public offering in 2010. Dr. Hundal has a broad range of relevant expertise including working in oncology with phage display and peptides, and has held strategic and transactional business development roles at PREACIS Pharmaceuticals, Xcellsyz, Albireo, Roche and AstraZeneca.
ThromboGenics and Bicycle Therapeutics Seal Cooperation Agreement on Novel Ophthalmic Medicines
Sep 6 13
ThromboGenics announced that it has entered into a collaboration and licence agreement with Bicycle Therapeutics for the development and commercialisation of novel drugs that inhibit a particular target for the treatment of ophthalmic diseases, such as diabetic macular oedema/edema (DME). In particular, ThromboGenics intends to use the Bicycle Therapeutics bicyclic peptides for developing therapeutics that inhibit a target involved in vascular permeability. The companies will be collaborating on the preclinical development of these bicyclic peptide inhibitors; while ThromboGenics has an exclusive licence to take up the clinical development and commercialisation of identified drug candidates. In its turn, Bicycle will receive an upfront payment as well as development and regulatory milestone payments, and sales royalties, the details of which have not been disclosed. Significance: The selective inhibition of a target involved in vascular permeability is a new approach that could potentially help improve the DME treatment, a condition that affects around 30% of all patients who have suffered from diabetes for over 20 years and are at risk of developing the condition.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 14, 2014
Most Searched Private Companies
Sponsored Financial Commentaries